Brind.
  1. CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.
  2. GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.

GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.

1 report, 1 independent Updated Aug 8
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.

Who's involved

What this event is mainly about
CureVacGSKPfizer

Keep exploring

Part of

GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic. All 1 developments

Within CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • BioPharma DiveBioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharm